摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Octahydrocyclopenta[c]pyrrole-1-carboxylic acid hydrochloride | 1219204-23-5

中文名称
——
中文别名
——
英文名称
Octahydrocyclopenta[c]pyrrole-1-carboxylic acid hydrochloride
英文别名
1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole-3-carboxylic acid;hydrochloride
Octahydrocyclopenta[c]pyrrole-1-carboxylic acid hydrochloride化学式
CAS
1219204-23-5
化学式
C8H14ClNO2
mdl
MFCD20039926
分子量
191.65
InChiKey
MIIHGYVJEBVNQB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.86
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.875
  • 拓扑面积:
    49.3
  • 氢给体数:
    3
  • 氢受体数:
    3

文献信息

  • COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION
    申请人:Holsinger Leslie Jean
    公开号:US20090270415A1
    公开(公告)日:2009-10-29
    The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
    本发明涉及具有双重性质的化合物,既具有作为蛋白酶S抑制剂的作用,又具有抑制HCV复制的作用。因此,这些化合物对治疗包括丙型肝炎、阿尔茨海默病和自身免疫性疾病等疾病状态有用。本发明还涉及含有这些化合物的制药组合物以及制备这些化合物的过程。
  • BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
    申请人:Codexis, Inc.
    公开号:EP2307419A2
    公开(公告)日:2011-04-13
  • US8106059B2
    申请人:——
    公开号:US8106059B2
    公开(公告)日:2012-01-31
  • [EN] COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION<br/>[FR] COMPOSÉS CAPABLES D'INHIBER LA PROTÉASE CATHEPSINE S ET LA RÉPLICATION DU HCV
    申请人:VIROBAY INC
    公开号:WO2009055467A2
    公开(公告)日:2009-04-30
    The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
  • [EN] BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS<br/>[FR] PROCÉDÉS BIOCATALYTIQUES POUR LA PRÉPARATION DE COMPOSÉS DE PROLINE BICYCLIQUES CONDENSÉS SENSIBLEMENT PURS SUR LE PLAN STÉRÉO-ISOMÉRIQUE
    申请人:CODEXIS INC
    公开号:WO2010008828A2
    公开(公告)日:2010-01-21
    The present disclosure provides substantially stereomerically pure fused bicyclic proline compounds of structural Formulae II to VII as described herein, and to biocatalytic processes for their preparation, and to the enzymes used in those processes.
查看更多